Hot Biotech Stocks: BioDelivery Sciences International (NASDAQ:BDSI), Durata Therapeutics (NASDAQ:DRTX), Ardelyx (NASDAQ:ARDX), Gilead Sciences (NASDAQ:GILD)

Stock analysts at Roth Capital raised their price objective on shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI), from $15.50 to $16.50 in a report issued on Monday. Roth Capital’s target price would indicate a potential upside of 26.34% from the company’s current price. BioDelivery Sciences International, Inc. (NASDAQ:BDSI), weekly performance is 8.74%. On last trading day company shares ended up $13.06. Analysts mean target price for the company is $17.81. BioDelivery Sciences International, Inc. (NASDAQ:BDSI),distance from 50-day simple moving average (SMA50) is 28.71%.

Durata Therapeutics, Inc. (NASDAQ:DRTX), had its price objective raised by Roth Capital from $24.00 to $28.00 in a research report released on Tuesday morning. Durata Therapeutics, Inc. (NASDAQ:DRTX), fell 2.91% in last trading session and ended the day on $17.38. DRTX, return on assets is -65.00%. Durata Therapeutics, Inc. (NASDAQ:DRTX), quarterly performance is 34.83%.

Ardelyx, Inc. (NASDAQ:ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, announced the pricing of its initial public offering of 4,286,000 shares of common stock at a public offering price of $14.00 per share. The shares are expected to begin trading on The NASDAQGlobal Market under the ticker symbol “ARDX” on June 19, 2014. In addition, Ardelyx has granted the underwriters a 30-day option to purchase up to an additional 642,900 shares of common stock at the initial public offering price to cover over-allotments, if any. The offering is expected to close on June 24, 2014 subject to customary closing conditions. Ardelyx, Inc. (NASDAQ:ARDX), shares moved down 7.05% in last trading session and was closed at $19.00, while trading in range of $18.61 – 21.60. Ardelyx, Inc. (NASDAQ:ARDX), year to date (YTD) performance is 34.66%.

Gilead Sciences Inc. (NASDAQ:GILD), CEO John C. Martin sold 140,625 shares of the company’s stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $84.84, for a total transaction of $11,930,625.00. Following the transaction, the chief executive officer now directly owns 4,429,387 shares in the company, valued at approximately $375,789,193. Gilead Sciences Inc. (NASDAQ:GILD), ended the last trading day at $87.21. Company weekly volatility is calculated as 2.23% and price to cash ratio as 20.70. Gilead Sciences Inc. (NASDAQ:GILD), showed a positive weekly performance of 5.15%.